Early detection of arterial hardening using PeriScope as a predicative risk factor for future heart diseases following doxorubicin as chemotherapy for cancer treatment
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2022/04/041879
- Lead Sponsor
- Dr Mehdi Ali Mirza
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All patients receiving doxorubicin chemotherapy cumulative dose less than 360 mg/m2 for the first time.
2. Patients of either gender aged between 18 to 70 years.
3. Patient able to comply with the study related procedures.
Exclusion Criteria
1. Patients with pre-existing cardiac abnormalities
2. Patients with any limb deformities.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method